Quantcast

Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men.

Research paper by Magdalena M Bentmar Holgersson, Aleksander A Giwercman, , Anders A Bjartell, Frederick C W FC Wu, Ilpo T IT Huhtaniemi, Terence W TW O'Neill, Neil N Pendleton, Dirk D Vanderschueren, Michael E J ME Lean, Thang S TS Han, Joseph D JD Finn, Krzysztof K Kula, Gianni G Forti, Felipe F FF Casanueva, et al.

Indexed on: 12 Jul '14Published on: 12 Jul '14Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology



Abstract

Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer.Men without prostate cancer history (n = 1,744) were selected from the European Male Ageing Study cohort of 40 to 79-year-old men from eight different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR variants (CAG repeat-length and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cutoff concentrations for further investigation of prostate cancer.Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95% confidence intervals, 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG repeats (median 20 vs. 23, P < 0.0005), but CAG repeat length per se did not affect the PSA concentrations.The A-allele of the SNP rs1204038 gives a 65% higher risk of having PSA above 3 ng/mL than the G-allele in men without prostate cancer, and thereby an increased risk of being referred for further examination on suspicion of prostate cancer.Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.

More like this: